A Phase 3 interventional study of Atacicept and Placebo to match Atacicept in IgA Nephropathy and Berger Disease, sponsored by Vera Therapeutics, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Vera Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Glomerulonephritis, IGA with a site in United States — 27 open to participants now, 39 under way, 18 of them phase 3. Glomerulonephritis, IGA · United States.
Among the 75 studies in Glomerulonephritis, IGA with a site in United States, this one is the 12th largest by enrollment of the 69 interventional ones that give a count, is one of 6 that started in 2023, is one of 23 in phase 3, reaches primary completion later than 1 of the 38 other live ones, and was the 32nd registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.
Browse Glomerulonephritis, IGA studies →27 of the 75 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Israel
Ages 18+
argenx · Sites in United States, Japan
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 24 · Phase 4 7
First in 1997; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 428 is above the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 72 across the 69 interventional studies, 744 across the 6 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 75 have an industry lead sponsor. The 10 most frequent:
Vera Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Vera Therapeutics, Inc. has 4 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
8 of the studies in Glomerulonephritis, IGA with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06712407Calliditas Therapeutics ABEfficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | 2027-03 |
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT05003986Travere Therapeutics, Inc.Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | 2027-03-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 75 studies in Glomerulonephritis, IGA with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
This is a multi-part study comprising of the original Phase 2b study and the addition of a separate pivotal Phase 3 study.
After the completion of the primary results for the Ph 2b dose ranging study, the pivotal study will evaluate the efficacy and safety of atacicept compared to placebo in reducing proteinuria in subjects with IgAN and persistent proteinuria despite being on a maximally tolerated dose (MTD) of a RASi. Safety, eGFR, serum immunoglobulins and Gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 104wk double-blind treatment period, followed by a 52wk open-label treatment period and a 26wk safety follow-up period. The UPCR primary endpoint will be assessed after the first 200 patients are randomized.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atacicept 150mg once weekly subcutaneous (SC) injections
Biological: Atacicept
Placebo to match Atacicept once weekly subcutaneous (SC) injection
Other: Placebo to match Atacicept
Once weekly subcutaneous (SC) injections by prefilled syringe
Also known as: VT-001
Once weekly subcutaneous (SC) injections by prefilled syringe
Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)
Percentage reduction in UPCR was obtained from geometric mean ratios. The natural log-transformed ratio of UPCR to its baseline value was analyzed using a Mixed Model for Repeated Measures (MMRM), adjusted by baseline variables specified in the Statistical Analysis Plan (SAP), including data from baseline up to Week 36 during the Double-Blind period.
Time frame: 36 Weeks
| Milestone | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) |
|---|---|---|
| Started | 214 | 214 |
| Completed | 0 | 0 |
| Not completed | 214 | 214 |
Percentage reduction in UPCR was obtained from geometric mean ratios. The natural log-transformed ratio of UPCR to its baseline value was analyzed using a Mixed Model for Repeated Measures (MMRM), adjusted by baseline variables specified in the Statistical Analysis Plan (SAP), including data from baseline up to Week 36 during the Double-Blind period.
| mean UPCR percent Change at Week 36 | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) |
|---|---|---|
| Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) | -46 (-53 to -38) | -7 (-19 to 8) |
Collected over Data entered is representative of the 36 week interim analysis and will be updated with the final analysis at 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atacicept Dose 150mg | 0/214 (0%) | 1/214 (0.5%) | 81/214 (37.9%) |
| Placebo to Match Atacicept (Part C/D) | 0/214 (0%) | 11/214 (5.1%) | 34/214 (15.9%) |
| Event | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) |
|---|---|---|
| GastroenteritisInfections and infestations | 0/214 | 1/214 |
| Lower respiratory tract infectionInfections and infestations | 0/214 | 1/214 |
| PneumoniaInfections and infestations | 0/214 | 1/214 |
| PyelonephritisInfections and infestations | 0/214 | 1/214 |
| CholecystitisHepatobiliary disorders | 1/214 | 0/214 |
| Cholecystitis acuteHepatobiliary disorders | 0/214 | 1/214 |
| IgA nephropathyRenal and urinary disorders | 0/214 | 1/214 |
| Renal impairmentRenal and urinary disorders | 0/214 | 1/214 |
| Acute myocardial infarctionCardiac disorders | 0/214 | 1/214 |
| HyponatraemiaMetabolism and nutrition disorders | 0/214 | 1/214 |
| Event | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) |
|---|---|---|
| Injection site reactionSkin and subcutaneous tissue disorders | 41/214 | 4/214 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 26/214 | 19/214 |
| NasopharyngitisInfections and infestations | 17/214 | 13/214 |
| Injection site erythemaSkin and subcutaneous tissue disorders | 12/214 | 1/214 |
| Age, Customized(Participants) | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) | Total |
|---|---|---|---|
| <45 | 129 | 132 | 261 |
| >=45-<65 | 80 | 76 | 156 |
| >=65 | 5 | 6 | 11 |
| Sex: Female, Male(Participants) | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) | Total |
|---|---|---|---|
| Female | 92 | 82 | 174 |
| Male | 122 | 132 | 254 |
| Race/Ethnicity, Customized(Participants) | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 15 | 42 |
| Not Hispanic or Latino | 187 | 199 | 386 |
| Region of Enrollment(Participants) | Atacicept Dose 150mg | Placebo to Match Atacicept (Part C/D) | Total |
|---|---|---|---|
| India | 29 | 31 | 60 |
| United States | 22 | 20 | 42 |
| Japan | 18 | 16 | 34 |
| South Korea | 16 | 15 | 31 |
| Turkey (Türkiye) | 15 | 15 | 30 |
| Philippines | 10 | 10 | 20 |
| Brazil | 9 | 9 | 18 |
| China | 7 | 9 | 16 |
| Poland | 6 | 10 | 16 |
| Malaysia | 8 | 7 | 15 |
| United Kingdom | 8 | 6 | 14 |
| Argentina | 10 | 3 | 13 |
| Denmark | 5 | 7 | 12 |
| Ireland | 6 | 6 | 12 |
| Sri Lanka | 7 | 5 | 12 |
| Thailand | 2 | 8 | 10 |
| Australia | 6 | 2 | 8 |
| Belgium | 3 | 5 | 8 |
| Taiwan | 4 | 4 | 8 |
| Canada | 5 | 2 | 7 |
| Czechia | 3 | 4 | 7 |
| Germany | 4 | 3 | 7 |
| Greece | 1 | 6 | 7 |
| Spain | 3 | 4 | 7 |
| Croatia | 2 | 3 | 5 |
| Hong Kong | 1 | 1 | 2 |
| Portugal | 1 | 1 | 2 |
| Singapore | 2 | 0 | 2 |
| Estonia | 0 | 1 | 1 |
| France | 0 | 1 | 1 |
| Italy | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in May 2025, 22 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein
Vera Therapeutics, Inc.